‘Breakthrough’ mRNA cancer drug curbs melanoma in large trial
US drugmakers Merck and Moderna said Wednesday a personalized cancer treatment had shown success in reducing the recurrence of melanoma tumors in a late-stage trial hailed by experts as a “breakthrough.”The news sent shares in Moderna soaring 145 percent to $154 while Merck’s stock was up more than 12 percent to $152. The drug, called […]
Read More